度普利尤单抗使泛发性结节性痒疹显著改善。 - Suppr

Suppr

超能文献

Dramatic improvement of generalized prurigo nodularis with dupilumab.

作者信息

Calugareanu A, Jachiet M, Lepelletier C, De Masson A, Rybojad M, Bagot M, Bouaziz J D

机构信息

Dermatology Department, Saint-Louis Hospital, APHP, Paris, France.

Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.

出版信息

J Eur Acad Dermatol Venereol. 2019 Aug;33(8):e303-e304. doi: 10.1111/jdv.15584. Epub 2019 May 8.

DOI:10.1111/jdv.15584

PMID:30893496

Abstract

摘要

相似文献

Dramatic improvement of generalized prurigo nodularis with dupilumab.

J Eur Acad Dermatol Venereol. 2019 Aug;33(8):e303-e304. doi: 10.1111/jdv.15584. Epub 2019 May 8.

Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.

J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e74-e76. doi: 10.1111/jdv.15957. Epub 2019 Oct 17.

Safety and Effectiveness of Dupilumab in Prurigo Nodularis.

J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):162-163. doi: 10.18176/jiaci.0550. Epub 2020 Jun 23.

Dupilumab for the Treatment of Prurigo Nodularis.

Skin Therapy Lett. 2023 Nov;28(6):7-9.

Dupilumab: Mechanism of action, clinical, and translational science.

Clin Transl Sci. 2024 Aug;17(8):e13899. doi: 10.1111/cts.13899.

Dupilumab Treatment for Generalized Prurigo Nodularis.

JAMA Dermatol. 2019 Jan 1;155(1):118-120. doi: 10.1001/jamadermatol.2018.3912.

Dupilumab for pediatric prurigo nodularis: A case report.

Pediatr Dermatol. 2021 Jan;38(1):334-335. doi: 10.1111/pde.14464. Epub 2020 Nov 28.

Dupilumab for prurigo nodularis: Case series and review of the literature.

Dermatol Ther. 2020 Mar;33(2):e13222. doi: 10.1111/dth.13222. Epub 2020 Jan 16.

Dupilumab for treatment-refractory prurigo nodularis.

J Dtsch Dermatol Ges. 2020 Jun;18(6):618-624. doi: 10.1111/ddg.14107. Epub 2020 May 29.

Efficacy and safety of dupilumab in patients with prurigo nodularis.

Arch Dermatol Res. 2024 Oct 14;316(10):676. doi: 10.1007/s00403-024-03387-1.

引用本文的文献

Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab.

J Allergy Clin Immunol. 2024 Jan;153(1):146-160. doi: 10.1016/j.jaci.2023.07.005. Epub 2023 Jul 26.

Dupilumab in Inflammatory Skin Diseases: A Systematic Review.

Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634.

Dupilumab for the treatment of prurigo nodularis: A systematic review.

Front Immunol. 2023 Jan 20;14:1092685. doi: 10.3389/fimmu.2023.1092685. eCollection 2023.

Immunotargets and Therapy for Prurigo Nodularis.

Immunotargets Ther. 2022 Apr 26;11:11-21. doi: 10.2147/ITT.S316602. eCollection 2022.

Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.

J Invest Dermatol. 2021 Sep;141(9):2208-2218.e14. doi: 10.1016/j.jid.2021.02.749. Epub 2021 Mar 23.

Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction.

Acta Derm Venereol. 2021 Feb 17;101(2):adv00403. doi: 10.2340/00015555-3726.

Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study.

Acta Derm Venereol. 2020 Apr 21;100(8):adv00119. doi: 10.2340/00015555-3471.

Chronic Pruritus Responding to Dupilumab-A Case Series.

Medicines (Basel). 2019 Jun 29;6(3):72. doi: 10.3390/medicines6030072.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Dramatic improvement of generalized prurigo nodularis with dupilumab.

J Eur Acad Dermatol Venereol. 2019 Aug;33(8):e303-e304. doi: 10.1111/jdv.15584. Epub 2019 May 8.

Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients.

J Eur Acad Dermatol Venereol. 2020 Feb;34(2):e74-e76. doi: 10.1111/jdv.15957. Epub 2019 Oct 17.

Safety and Effectiveness of Dupilumab in Prurigo Nodularis.

J Investig Allergol Clin Immunol. 2021 Apr 20;31(2):162-163. doi: 10.18176/jiaci.0550. Epub 2020 Jun 23.

Dupilumab for the Treatment of Prurigo Nodularis.

Skin Therapy Lett. 2023 Nov;28(6):7-9.

Dupilumab: Mechanism of action, clinical, and translational science.

Clin Transl Sci. 2024 Aug;17(8):e13899. doi: 10.1111/cts.13899.

Dupilumab Treatment for Generalized Prurigo Nodularis.

JAMA Dermatol. 2019 Jan 1;155(1):118-120. doi: 10.1001/jamadermatol.2018.3912.

Dupilumab for pediatric prurigo nodularis: A case report.

Pediatr Dermatol. 2021 Jan;38(1):334-335. doi: 10.1111/pde.14464. Epub 2020 Nov 28.

Dupilumab for prurigo nodularis: Case series and review of the literature.

Dermatol Ther. 2020 Mar;33(2):e13222. doi: 10.1111/dth.13222. Epub 2020 Jan 16.

Dupilumab for treatment-refractory prurigo nodularis.

J Dtsch Dermatol Ges. 2020 Jun;18(6):618-624. doi: 10.1111/ddg.14107. Epub 2020 May 29.

Efficacy and safety of dupilumab in patients with prurigo nodularis.

Arch Dermatol Res. 2024 Oct 14;316(10):676. doi: 10.1007/s00403-024-03387-1.

引用本文的文献

Single-cell profiling of prurigo nodularis demonstrates immune-stromal crosstalk driving profibrotic responses and reversal with nemolizumab.

J Allergy Clin Immunol. 2024 Jan;153(1):146-160. doi: 10.1016/j.jaci.2023.07.005. Epub 2023 Jul 26.

Dupilumab in Inflammatory Skin Diseases: A Systematic Review.

Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634.

Dupilumab for the treatment of prurigo nodularis: A systematic review.

Front Immunol. 2023 Jan 20;14:1092685. doi: 10.3389/fimmu.2023.1092685. eCollection 2023.

Immunotargets and Therapy for Prurigo Nodularis.

Immunotargets Ther. 2022 Apr 26;11:11-21. doi: 10.2147/ITT.S316602. eCollection 2022.

Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.

J Invest Dermatol. 2021 Sep;141(9):2208-2218.e14. doi: 10.1016/j.jid.2021.02.749. Epub 2021 Mar 23.

Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction.

Acta Derm Venereol. 2021 Feb 17;101(2):adv00403. doi: 10.2340/00015555-3726.

Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study.

Acta Derm Venereol. 2020 Apr 21;100(8):adv00119. doi: 10.2340/00015555-3471.

Chronic Pruritus Responding to Dupilumab-A Case Series.

Medicines (Basel). 2019 Jun 29;6(3):72. doi: 10.3390/medicines6030072.